ME/CFS pathophysiology
ME/CFS is a complex neuroimmune condition. Emerging research has identified several overlapping pathological mechanisms:
- Mitochondrial dysfunction:Multiple studies document impaired mitochondrial function in ME/CFS — reduced ATP production, elevated lactate (indicating anaerobic shift), and abnormal mitochondrial morphology in leukocytes and muscle cells. AMPK signalling is dysregulated, impairing the switch to oxidative phosphorylation during energy demand.
- NADPH oxidase activation:NOX2 (NADPH oxidase isoform 2) is constitutively elevated in ME/CFS — generating superoxide that damages mitochondrial membranes, impairs electron transport chain function, and creates a self-amplifying cycle of oxidative damage and mitochondrial dysfunction.
- Neuroinflammation:PET imaging and CSF cytokine studies show elevated microglial activation and neuroinflammatory markers in ME/CFS. IL-6 and TNF-α correlate with symptom severity. This neuroinflammation impairs HPA axis function and drives the cognitive symptoms (“brain fog”).
- Post-exertional malaise (PEM):The hallmark of ME/CFS — exertion beyond a patient-specific threshold causes symptom exacerbation lasting 12–48+ hours. The mechanism involves failure to upregulate oxidative phosphorylation during exercise, excessive anaerobic metabolism, and post-exercise NADPH oxidase activation amplification.
Phycocyanobilin: the primary relevant mechanism
Phycocyanobilin (PCB) — the chromophore of phycocyanin — is a structural analogue of biliverdin, the product of haem oxygenase-1. Both biliverdin and PCB inhibit NADPH oxidase. PCB is orally bioavailable, crosses the blood-brain barrier, and provides sustained NADPH oxidase inhibition in both peripheral tissue and neuronal cells.
In ME/CFS terms, this means:
- Reduced superoxide generation in mitochondrial membranes — breaking the oxidative damage cycle that perpetuates mitochondrial dysfunction
- Reduced microglial NADPH oxidase activation — neuroinflammation attenuation and potential improvement in cognitive symptoms
- Reduced post-exercise oxidative burst — potentially raising the PEM threshold (the amount of exertion tolerable before symptom amplification)
No clinical trial has tested phycocyanin or spirulina specifically in ME/CFS patients. This is mechanistic reasoning, not clinical evidence — but the mechanism is precise and directly targets the documented pathological pathways.
Iron deficiency in ME/CFS
Sub-clinical iron deficiency is disproportionately prevalent in ME/CFS populations — partly because the condition affects activity levels and dietary diversity, partly because inflammatory cytokines upregulate hepcidin, which reduces intestinal iron absorption.
Iron deficiency worsens ME/CFS through multiple pathways:
- Impaired mitochondrial function — iron-sulfur clusters in the electron transport chain require iron for assembly
- Reduced haemoglobin and tissue oxygen delivery — worsening cellular energy production
- Impaired monoamine synthesis — tryptophan hydroxylase and tyrosine hydroxylase both need iron, affecting serotonin, dopamine, and norepinephrine synthesis relevant to cognitive and mood symptoms
The pacing principle and spirulina
Pacing (staying within the anaerobic threshold to avoid PEM) is the primary management strategy for ME/CFS. Supplements that might theoretically increase energy or exercise capacity require caution — doing more because you feel slightly better can trigger a severe PEM crash.
Spirulina is not an energy booster or stimulant. Its mechanism (NADPH oxidase inhibition, mitochondrial protection, iron provision) operates at a cellular level without creating a subjective energy surge that might encourage overexertion. This is an important distinction from caffeine or B12 injections (which can create stimulatory effects leading to boom-bust cycles in ME/CFS).
Dosing considerations in ME/CFS
- Start at 1–2 g/day — ME/CFS patients have heightened sensitivity to new interventions and the prebiotic polysaccharides in spirulina can cause initial GI symptoms
- Escalate slowly over 4–8 weeks to 4–6 g/day
- Monitor symptoms during escalation — if fatigue worsens, reduce and hold (rare, but immune stimulation from spirulina may temporarily exacerbate neuroinflammatory symptoms in a small subset)
- Target 5–6 g/day for sustained NADPH oxidase inhibition — the dose range used in oxidative stress trials
What spirulina is not in ME/CFS
- Not a cure or primary treatment — graded exercise therapy (GET) is now largely contra-indicated in ME/CFS; pacing and symptom management remain the primary approach
- Not a replacement for ME/CFS specialist care — the condition is complex and spirulina is one potential adjunct in a multi-component management plan
- Not validated in ME/CFS patients specifically — the mechanistic rationale is strong but the absence of clinical trial data means individual responses will vary